Research projects

Clinical Trials and Therapeutics
Combining Memantine and Cholinesterase inhibitors in Lewy body dementia treatment trial (COBALT)

Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are two neurodegenerative cause of dementia, in which patients are generally treated with Cholinesterase inhibitors. This is an NIHR Health Technology Assessment funded international multi-centre trial examining the efficacy of combined treatment with Memantine. The Southampton site for this trial is the Memory Assessment and Research Centre, Moorgreen Hospital.

Dr Jay Amin, Professor Clive Holmes

Related projects:

Using electronic patient records to examine patient outcomes in Dementia with Lewy bodies

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative cause of dementia. However, people with DLB often experience missed or delayed diagnosis. The Clinical Record Interactive Search (CRIS) system allows research and service …

Phase 1 trial of bepranemab in progressive supranuclear palsy

Phase 1 trial of bepranemab in progressive supranuclear palsy

Use of antisense oligonucleotide in Progressive supranuclear palsy

Phase 1 first in human clinical trial in patients with progressive supranuclear palsy.

Treating impulsivity in people with progressive supranuclear palsy

Phase 2/3 clinical trial investigating the use of Atomoxetine to treat impulsivity